Irmak Karaca, MD
Ophthalmology · New York, NYNPI 1760101778
Payments from drug & device makers
What this record shows
This record is dominated by grants: $125,913 of the $128,727 with a category attached, or 97.8%. Regeneron accounts for 98.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $69,934 and has fallen 98.8% since, to $865 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $1693.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$126K
- AbbVie$396
- Alcon$376
- Genentech USA, Inc.$335
- Mallinckrodt Hospital Products Inc.$306
- Biogen$297
- plus $858 from 7 others
What the payments were for
- Grants$125,91398%
- Travel & lodging$2250%
- Food & beverage$2,5892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 46 | $126,160 |
| AbbVie | 4 | $396 |
| Alcon | 2 | $376 |
| Genentech USA, Inc. | 5 | $335 |
| Mallinckrodt Hospital Products Inc. | 7 | $306 |
| Biogen | 3 | $297 |
| Apellis Pharmaceuticals, Inc. | 3 | $202 |
| Astellas Pharma US Inc | 1 | $151 |
| Neurotech Pharmaceuticals, Inc. | 1 | $139 |
| Genentech, Inc. | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Alimera Sciences, Inc. | 1 | $92 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$128,727 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 82 | $666,887 |
| Mycophenolate Mofetil | 56 | $9,829 |
| Difluprednate | 15 | $2,041 |
| Prednisolone Acetate | 44 | $1,993 |
| MethotrexateMethotrexate Sodium | 51 | $1,835 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $1,834 |
| ValacyclovirValacyclovir Hcl | 28 | $1,647 |
| Ketorolac Tromethamine | 24 | $993 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $376 |
| Prednisone | 19 | $353 |
| Latanoprost | 22 | $202 |
| Brimonidine Tartrate | 18 | $129 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.